SCHEMBL6796548

SCHEMBL6796548

COc1ccc(/C=C2/N=C(c3ccccc3)OC2=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
TNNI3 P19429 1/20 0.67
CRHBP P24387 1/20 0.67
TNNT2 P45379 1/20 0.67
TNNC1 P63316 1/20 0.67
CRHR2 Q13324 1/20 0.67
ALDH1A1 P00352 3/20 0.64
PLCG2 P16885 1/20 0.64
MAPT P10636 2/20 0.63
KDM4E B2RXH2 1/20 0.63
CSNK2A2 P19784 2/20 0.62
CSNK2B P67870 2/20 0.62
CSNK2A1 P68400 2/20 0.62
F2 P00734 1/20 0.61
F10 P00742 1/20 0.61
PLG P00747 1/20 0.61
PLAU P00749 1/20 0.61
PLAT P00750 1/20 0.61
KLKB1 P03952 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15421524 1.00 MEN1 (0.67) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL6796550 1.00 MEN1 (0.67) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL6795524 0.94 ALDH1A1 (0.67) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL6795520 0.94 ALDH1A1 (0.67) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL1241572 0.94 ALDH1A1 (0.62) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL6797935 0.89 PLCG2 (0.67) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL6797933 0.89 PLCG2 (0.67) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL11974092 0.88 PLCG2 (0.78) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL29518211 0.87 CSNK2A2 (0.78) MEN1KMT2ATNNI3CRHBPTNNT2
SCHEMBL22505155 0.87 CSNK2A2 (0.78) MEN1KMT2ATNNI3CRHBPTNNT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed
EP-3894914-B1 OPHTHALMIC LENS COMPRISING AN OXAZOLONE ESSILOR INT (FR) 2023-11-22 EP disclosed
US-20220146712-A1 OPHTHALMIC LENS COMPRISING AN OXAZOLONE ESSILOR INTERNATIONAL (FR) 2022-05-12 US disclosed
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 MEN1 2646/4885KMT2A 4782/4885TNNI3 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.